Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease by Torsten Falk et al.
BioMed CentralMolecular Neurodegeneration
ssOpen AcceShort report
Vascular endothelial growth factor B (VEGF-B) is up-regulated and 
exogenous VEGF-B is neuroprotective in a culture model of 
Parkinson's disease
Torsten Falk*†, Shiling Zhang† and Scott J Sherman
Address: College of Medicine, University of Arizona, Department of Neurology, Tucson, AZ 85724, USA
Email: Torsten Falk* - tfalk@u.arizona.edu; Shiling Zhang - shiling@email.arizona.edu; Scott J Sherman - ssherman@u.arizona.edu
* Corresponding author    †Equal contributors
Abstract
Parkinson's disease (PD) results from the degeneration of dopaminergic neurons in the substantia
nigra and the consequent deficit of dopamine released in the striatum. Current oral dopamine
replacement or surgical therapies do not address the underlying issue of neurodegeneration, they
neither slow nor halt disease. Neurotrophic factors have shown preclinical promise, but the choice
of an appropriate growth factor as well as the delivery has proven difficult. In this study, we used a
rotenone rat midbrain culture model to identify genes that are changed after addition of the
neurotoxin. (1) We challenged rat midbrain cultures with rotenone (20 nM), a pesticide that has
been shown to be toxic for dopaminergic neurons and that has been a well-characterized model of
PD. A gene chip array analysis demonstrated that several genes were up-regulated after the
rotenone treatment. Interestingly transcriptional activation of vascular endothelial growth factor B
(VEGF-B) was evident, while vascular endothelial growth factor A (VEGF-A) levels remained
unaltered. The results from the gene chip array experiment were verified with real time PCR and
semi-quantitative western analysis using β-actin as the internal standard. (2) We have also found
evidence that exogenously applied VEGF-B performed as a neuroprotective agent facilitating
neuron survival in an even more severe rotenone culture model of PD (40 nM rotenone). VEGF-
B has very recently been added to the list of trophic factors that reduce effects of
neurodegeneration, as was shown in an in vivo model of motor neuron degeneration, while lacking
potential adverse angiogenic activity. The data of an in vivo protective effect on motor neurons
taken together with the presented results demonstrate that VEGF-B is a new candidate trophic
factor distinct from the GDNF family of trophic factors. VEGF-B is activated by neurodegenerative
challenges to the midbrain, and exogenous application of VEGF-B has a neuroprotective effect in a
culture model of PD. Strengthening this natural protective response by either adding exogenous
VEGF-B or up-regulating the endogenous VEGF-B levels may have the potential to be a disease
modifying therapy for PD. We conclude that the growth factor VEGF-B can improve neuronal
survival in a culture model of PD.
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The two most pressing therapeutic challenges in PD are to
(1) provide a stable level of dopamine replacement and
(2) slow disease progression [1-4]. Neurotrophic growth
factors such as the glial-derived neurotrophic factor
(GDNF), neurturin, FGF-2 and others, have shown great
promise in experimental models of PD [5,6]. The hope is
that using these factors in human PD could provide a
potent disease-modifying therapy; however, clinical
development of these agents is problematic [5]. Intracere-
broventricular administration of GDNF via a micro pump
[7] and neurturin delivery via viral vector-mediated gene
transfer [8] ultimately failed in Phase II clinical trials.
These disappointing results despite robust preclinical data
could be due to problems with the delivery method or
choice of neurotrophic factor.
One path to identify new potential modifiers of PD is by
using gene chip arrays utilizing in vitro and in vivo models
of PD. In this study, to identify candidate genes, we chal-
lenged rat midbrain cultures with rotenone, a pesticide
that has been shown to be toxic for dopaminergic neurons
and that has been a well-characterized model of PD
[9,10].
Timed-pregnant Sprague-Dawley rats were anesthetized
by exposure to CO2 and sacrificed. Fetuses were removed
at E17, anesthetized by cooling on ice, decapitated, and
the midbrain was dissected. Details of the methods have
been reported [11,12]. Tissue culture media and sera were
obtained from Gibco-BRL, Grand Island, NY. The proce-
dure was approved by the IACUC at the University of Ari-
zona and conformed to the guidelines of the National
Institutes of Health. The number of animals used and
their suffering was minimized. We developed protocols in
vitro using rotenone (Sigma-Aldrich, St. Louis, MO) to
produce damage to dopaminergic neurons by adding it at
the indicated concentrations at day 6 in culture. In previ-
ous work [11], an initial rotenone concentration response
curve was established and the LD50 for 5 day exposure
was found to be 25-50 nM. We chose to look at a slightly
lower concentration of rotenone (20 nM), since we were
interested in changes in mRNA before the cells are lost.
We isolated the mRNA of 11 day old cultures 5 days after
the rotenone challenge, and of untreated control cultures,
before performing a gene array analysis (n = 3 separate
experiments). The RNA isolation was done with the Qia-
gen RNA kit (Qiagen, Valencia, CA), using the manufac-
turers protocol. The gene array analysis was carried out
using the GeneChip Rat Genome 230 2.0 Array (Affymet-
rics, Santa Clara, CA) and standard procedure. Data was
analysed using the limma software package [13,14].
Thirty-eight genes were up-regulated (using adjusted P =
0.025 and B = 2.5 as cutoff value; Table 1) after the roten-
one treatment, and transcriptional activation of VEGF-B,
but not of VEGF-A was evident. The results from the gene
chip array experiment were verified with real time PCR
(Figure 1), using β-actin as internal standard. Oligonucle-
otide primer sets that had been previously optimized for
quantitative PCR. The PCR was perfomed on an ABI 7300
system (Applied Biosystems Inc., Foster City, CA).
To further validate these results a semi-quantitative west-
ern analysis was conducted. This experiment demon-
strated an increase in protein expression of VEGF-B
Up-regulation of VEGF-B transcript, but not of VEGF-A tran-script, after rotenone (20 nM) trea ment of midbrain culturesFigure 1
Up-regulation of VEGF-B transcript, but not of 
VEGF-A transcript, after rotenone (20 nM) treat-
ment of midbrain cultures. The fold-increase of tran-
script vs. control as determined with real time PCR is shown 
as mean ± s.e.m for VEGF-B (black bar) and VEGF-A (shaded 
bar); n = 7 separate experiments. Mean fold changes in 
rotenone-treated cultures compared to control (± s.e.m.) 
were: VEGF-B = 1.65 ± 0.29; P = 0.026; VEGF-A = 1.25 ± 
0.20; P = 0.40. Statistical significance was determined by a 
two-tail t test of ΔΔCt and difference from control is 
depicted by an asterisk. Oligonucleotide Primers from 
Applied Biosystems Inc., Foster City, CA were used: VEGF-A 
(Rn01511602_m1); VEGF-B (Rn01454585_g1); β-actin 
(Rn00667869_m1). The TaqMan® MGB probe used at a con-
centration of 5 μM, comprised of a FAM™ reporter dye at 
the 5' end and a nonfluorescent quencher at the 3' end of the 
probe. The solution also contained the necessary primers at 
a concentration of 18 μM each.Page 2 of 7
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reaching significance at 25 nM rotenone. The highest
rotenone concentration (40 nM) did lead to the highest
expression of VEGF-B (Figure 2A and 2B).
With all techniques we saw a significant increase of VEGF-
B after rotenone challenge, while there wass no significant
change in VEGF-A mRNA level. This struck our interest in
light of the recently published results from Poesen et al.,
2008 [15], proving VEGF-B to be an inducible trophic fac-
tor in a model of neurodegeneration of motor neurons.
VEGF-B is a member of the VEGF-family of trophic factors
[16,17]. VEGF-A is the best studied member due to its
strong angiogenic activity and potential for cardiovascular
and cancer research [18]. VEGF-A is up-regulated in the
substantia nigra but not in the striatum of PD patients
[19]. VEGF-B, on the other hand, stimulates proliferation
of neuronal cultures in vitro [20], and has not been inves-
tigated in PD. VEGF-B has also recently been shown to be
neuroprotective in motor neuron degeneration in vivo
[15]. It had previously been shown to inhibit apoptosis
and having only minimal angiogenic activity [21] while
Table 1: List of the highest up-regulated genes in the gene array after rotenone treatment
gene_id ID adj. P value B value
Atf5 NM_172336 3.39E-05 9.733544
RGD1561519_predicted NM_001109112 0.003306 6.712279
Asns U07201 0.003466 6.388728
LOC690315 NM_001109577 0.004486 5.986556
Slc7a5 NM_017353 0.006186 5.572276
Sdf2l1_predicted NM_001109433 0.007716 5.109109
Lce1s_predicted XM_001066389 0.007716 5.029038
Slc7a3 NM_017217 0.0086 4.713449
Klhl6_predicted NM_001105867 0.0086 4.684208
Ns5atp9 NM_201418 0.008757 4.59833
Mrc1_predicted NM_001106123 0.009356 4.427766
Lrrc33 NM_001024995 0.009356 4.41691
LOC290651 NM_001013880 0.010522 4.201058
Pycs_predicted NM_001108524 0.010522 4.140525
Vegfb NM_053549 0.010522 4.090442
Shmt2 NM_001008322 0.010522 4.077214
Ncf1 NM_053734 0.010522 4.063953
Aldh1l2_predicted XM_235005 0.01345 3.812624
Mmp9 NM_031055 0.015332 3.603003
Dnajc3 NM_022232 0.015332 3.583457
Dpp7 NM_031973 0.015332 3.516206
Hmgcr NM_013134 0.015332 3.509113
Gpnmb NM_133298 0.015786 3.39472
Cndp2 NM_001010920 0.015786 3.37061
Pcp4 M24852 0.015786 3.355451
LOC680308 NM_001109398 0.016276 3.29948
Txnip NM_001008767 0.017441 3.210653
Eprs NM_001024238 0.018104 3.150337
Tm6sf1_predicted NM_001108490 0.019731 3.047957
Calr NM_022399 0.020863 2.959711
RGD1564553_predicted XM_577290 0.021343 2.854501
Yars NM_001025696 0.02214 2.778994
RGD1564228_predicted XM_001081442 0.02214 2.776624
Igf1 NM_178866 0.022922 2.701602
Hexb NM_001011946 0.022922 2.681626
Myo1f_predicted NM_001108076 0.023081 2.655012
Cd180_predicted NM_001106405 0.024702 2.574536
Cd68 NM_001031638 0.025665 2.501227
List of the top 38 up-regulated genes in the gene array after rotenone treatment (genes with significance values of both the adjusted P ≤ 0.025 and 
the false discovery rate log-odds score B>2.5 were included in the Table; n = 3 separate experiments). The P value is based upon a t test of the 
average ratio of expression values for the treated and untreated samples and adjusted for multiple testing using the false discovery rate, as 
implemented in the Bioconductor limma library http://www.bioconductor.org. B is the false discovery rate expressed as a log odds score, so B = 3 
means that there is 5% chance of being incorrect. VEGF-B is ranked 15th highest, and the B = 4.09 correlates to >98% chance that treatment is 
different form control. MMP9 is ranked 19th, and the B value = 3.60 correlates to >97% chance that treatment is different form control.Page 3 of 7
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important since efforts to use VEGF-A as a neurotrophic or
a neuroprotective factor had been hampered by the strong
angiogenic activity. Although neuroprotective effects of
VEGF-A expressed by cells or viral vectors in models of PD
were reported [23-25], they were over-shadowed by detri-
mental effects such as edema, ventriculomegaly [26] and
disruption of the blood brain barrier [27]. These negative
side effects were not seen when using VEGF-B in vivo [15].
Interestingly, the neuroprotective effect of VEGF-B in vivo
was also restricted to pathological conditions. Mice lack-
ing VEGF-B displayed normal motor behavior, but, when
challenged in a model of neurodegeneration, they dis-
played a more severe form of motor degeneration [15].
Loss of VEGF-B also enlarges stroke [20]. These data sug-
gest that VEGF-B plays a role in compensations for natural
disease processes of the nervous system. It does so by
binding to its only receptor VEGFR1 [18], a receptor with
not yet delineated downstream signaling events. Further
analysis of our gene array data showed the only up-regu-
lated gene with known interaction with VEGF-B was
matrix metallopeptidase 9 (MMP9). VEGFR1 signaling
has been previously linked to the induction of MMP9 in
lung endothelial cells [28] suggesting a potential role of
MMP9 in the effects of VEGF-B that should be further
investigated.
The fact that dopaminergic neurons make up less than 5%
of the cells in our midbrain preparation argues against an
up-regulation of VEGF-B only in dopaminergic neurons.
We therefore hypothesize that the VEGF-B may be
released by the astroglia in the preparation rather than the
dopaminergic neurons themselves. Further evidence sup-
porting this hypothesis comes from recent experiments
where rotenone treatment in vivo did not cause transcrip-
tional activation of VEGF-B in dopaminergic neurons ana-
lyzed after laser-capture microdissection [29]. In addition,
under healthy conditions, motor neurons express VEGF-B
to maintain neuroprotection in an autocrine manner,
whereas astrocytes may express VEGF-B after injury to
Semi-quantitative western analysis of VEGF-B expressionFigure 2
Semi-quantitative western analysis of VEGF-B expression. Midbrain cultures were exposed to 3 concentration of 
rotenone (16 nM, 25 nM and 40 nM) for 5 days. Protein was isolated and a western analysis was performed using a procedure 
previously published [32]. We used the expression of the house keeping β-actin protein (anti-β-actin antibody from Sigma-
Aldrich, St. Louis, MO) as the internal standard for the relative quantification of VEGF-B protein levels (anti-VEGF-B antibody 
from Santa Cruz Biotechnology, Santa Cruz, CA). A concentration-dependent increase in VEGF-B protein level was evident. In 
(A) example western blots for VEGF-B (on the left) and β-actin (on the right) are shown; the samples were run in triplicate. 
This was repeated with 3 separate preparations. The summary graph in (B) depicts the mean relative VEGF-B level (± s.e.m.) 
that was determined by densitometry using Image-J (Wayne Rasband, Bethesda, MD). Statistical significant differences from 
control were determined by one-way ANOVA followed by a Fisher LSD post hoc test, and are depicted by asterisks (*P < 
0.05, **P < 0.001). 40 nM rotenone induced a significantly greater increase than 16 nM and 25 nM rotenone (*P < 0.05). The 
statistical analyses were conducted using SPSS software, version 16.0 for Windows (SPSS, Chicago, IL).Page 4 of 7
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(A) Neurotrophic effect of VEGF-B167 on cultured rat midbrain dopaminergic neuronsFigur  3
(A) Neurotrophic effect of VEGF-B167 on cultured rat midbrain dopaminergic neurons. Mean count (± s.e.m.) of 
TH-positive neurons after immunocytochemical staining is plotted. Fluorescent images were acquired digitally on an Olympus 
IX70 inverted microscope and camera using Olympus MagnaFire software. Morphometric analysis was carried out using Image-
J (Wayne Rasband, Bethesda, MD). Antibodies were obtained from Chemicon, Temecula, CA. As compared to untreated con-
trol cultures (n = 22 culture dishes) a significant increase in the TH-positive neuron number per culture dish after addition of 
VEGF-B was apparent. The effect of VEGF-B on TH-positive cell number was concentration dependent. At 0.5 ng/ml (n = 8) no 
change was noticeable. At 2.5 ng/ml (n = 6) and 5 ng/ml (n = 10) a trend was evident, that reached a statistical significant level 
at 10 ng/ml (n = 12) and 22.5 ng/ml (n = 11). The mean effect remained the same at the highest tested concentration at 50 ng/
ml (n = 4, P = 0.051). Culture dishes were from 5 separate preparations. Data are plotted as mean ± s.e.m. (*P < 0.05; one-way 
ANOVA followed by a Games-Howell post hoc test to account for small group size and heterogeneity of variance). The statis-
tical significant differences from control are depicted by asterisks. (B) Neuroprotective effect of VEGF-B in a severe 
rotenone rat midbrain in vitro PD model. As compared to the untreated control cultures (n = 17; black bar) the TH-pos-
itive neuron number was reduced after addition of rotenone (40 nM; n = 11; gray bar on the left), this cell loss was rescued by 
adding 22.5 ng/ml VEGF-B167 (VEGF-B+40 nM rotenone; n = 9; gray patterned bar on the right) prior to rotenone (22.5 ng/ml 
VEGF-B only cultures; n = 9; black patterned bar). Data are plotted as mean ± s.e.m. (*P < 0.05; one-way ANOVA followed by 
a Fisher LSD post hoc test). The statistical significant difference from control is depicted by an asterisk. Culture dishes from 5 
separate preparations were used.
Molecular Neurodegeneration 2009, 4:49 http://www.molecularneurodegeneration.com/content/4/1/49maintain survival in a paracrine manner [15]. A similar
paracrine scenario is possible in the PD-like neurodegen-
eration induced in our model system. This hypothesis
should be tested in the future. Taken together with our
data showing an up-regulation of VEGF-B after rotenone
challenge to rat midbrain cultures, these data lead to our
hypothesis that VEGF-B may act as an endogenous trophic
factor against the neurodegenerative insult in a model of
PD.
We investigated the trophic activity further by adding
exogenous VEGF-B167 (0.5-50 ng/ml; R&D-Systems Inc.,
Minneapolis, MN) to midbrain cultures on day 6 (VEGF-
B167 is the more abundant of 2 splice isoforms, VEGF-B186
being the other). The cultures were fixed on day 11 and
dopaminergic cells were analyzed by tyrosine hydroxylase
(TH) immunocytochemical staining [11]. Neuronal num-
bers were determined by visual observation of randomly
chosen fields at 400× magnification, viewed with fluores-
cent optics to determine immunostained dopaminergic
neurons and with phase contrast to determine total cell
number. We saw a mean treatment effect of 30% increase
in TH-positive cell number per culture dish as compared
to the untreated cells, with a trend apparent at 2.5 ng/ml,
and statistical significance at 10 ng/ml. The mean effect
remained the same at the highest tested concentration at
50 ng/ml (Figure 3A). An experiment using 5 ng/ml of
VEGF-B186 showed also a significant effect (data not
shown). This is likely due to improvement in the native in
vitro survival of the dopaminergic neurons under artificial
culture conditions. Over the course of time in vitro, the
total number of neurons usually decreases. This is charac-
teristic of primary neurons in culture and likely reflects
normal developmental apoptosis and the absence of the
full complement of neurotrophic factors. A less likely
explanation could be stimulation of neurogenesis, but
this has not been demonstrated in the substantia nigra as
it has been for the subgranular zone of the hippocampal
dentate gyrus [30]. In a second series of experiments we
tested additional exogenous VEGF-B in the midbrain cul-
ture model using a severe challenge. Exposure to rotenone
(40 nM) for 5 days in culture led to a significant reduction
of TH-positive neurons per culture dish by 50% (P <
0.05). A neuroprotective effect against the rotenone chal-
lenge on TH-positive neurons was evident (Figure 3B)
with pretreatment with VEGF-B167 (22.5 ng/ml) 1 hour
prior to the toxin.
Neurotrophic factors are promising agents to provide dis-
ease modification for PD. This report demonstrates that
VEGF-B is a new candidate trophic factor distinct from the
GDNF-family of trophic factors, and is activated by neuro-
degenerative challenges to the midbrain. Strengthening
this natural protective response by either adding exoge-
nous VEGF-B or up-regulating the endogenous VEGF-B
levels may have the potential to be a disease modifying
therapy for PD. Based on the literature, the VEGF-B186 iso-
form is more diffusible than VEGF-B167 in vivo [15,31],
and therefore may have a greater therapeutic potential.
We conclude that the growth factor VEGF-B can improve
neuronal survival in a culture model of PD.
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